-
2024-514827-40-00
9
Patients with advanced soft-tissue sarcoma (leiomyosarcoma or malignan
-
2023-508547-51-00
5
2025-11-18
Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoco
-
2023-506784-33-00
5
2021-01-19
RET fusion-Positive NSCLC
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-511719-40-00
6
2024-10-09
Enterococcus faecalis infectious endocarditis
-
2023-509215-81-00
4
2024-05-22
Adult and young adult patients with diagnosis of advanced/metastatic s
-
2023-505929-14-00
5
2024-05-21
Systemic Lupus Erythematosus
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2023-503327-26-00
5
2024-01-31
Sjogren's syndrome
-
2023-503698-40-00
5
2023-03-23
Preeclampsia
-
2023-503435-17-00
5
2021-03-31
Juvenile psoriatic arthritis
-
2023-505673-32-00
5
2024-08-05
Hypophosphatasia
-
2023-509418-12-00
6
2024-06-05
Patients at risk of cardiovascular disease susceptible of receiving hi
-
2022-502975-45-00
5
2023-12-12
Metastatic leiomyosarcoma
-
2023-508498-97-00
5
2023-02-03
Systemic Lupus Erythematosus
-
2023-503467-41-00
5
2022-10-12
Relapsed or Refractory Multiple Myeloma
-
2023-508559-37-00
5
2022-07-14
Lupus nephritis
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-506786-63-00
5
2021-09-30
Breast Cancer
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2024-512704-20-00
4
2020-06-22
Unresectable and/or metastatic soft-tissue sarcoma after failure of at